SCHEMBL5074276

SCHEMBL5074276

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1ccc(O)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.47
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
CRHR1 P34998 2/20 0.39
BCHE P06276 1/20 0.38
TSHR P16473 3/20 0.37
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
CYP3A4 P08684 3/20 0.37
HPGD P15428 3/20 0.37
HSD17B10 Q99714 3/20 0.37
HDAC1 Q13547 1/20 0.37
PDE4B Q07343 2/20 0.37
TP53 P04637 1/20 0.36
HSD11B1 P28845 1/20 0.35
ATP4A P20648 1/20 0.35
ATP4B P51164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649712 0.97 C5AR1 (0.49) C5AR1ESR1ESR2CRHR1BCHE
SCHEMBL5135588 0.95 C5AR1 (0.45) C5AR1ESR1ESR2CRHR1BCHE
SCHEMBL5134990 0.92 C5AR1 (0.44) C5AR1ESR1ESR2CRHR1BCHE
SCHEMBL5134693 0.92 C5AR1 (0.45) C5AR1ESR1ESR2CRHR1BCHE
SCHEMBL5135148 0.92 C5AR1 (0.45) C5AR1ESR1ESR2CRHR1BCHE
SCHEMBL5135954 0.90 C5AR1 (0.44) C5AR1ESR1ESR2BCHETSHR
SCHEMBL5136142 0.90 C5AR1 (0.42) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL648508 0.90 C5AR1 (0.50) C5AR1ESR1ESR2CRHR1BCHE
SCHEMBL5073872 0.89 ESR1 (0.42) C5AR1ESR1ESR2CRHR1BCHE
SCHEMBL5072402 0.88 MAPT (0.43) C5AR1CRHR1BCHETSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed